


MS COVID BRIEFING

Update on ACT Accelerator & COVAX

22 JULY 2021



ACT-A update


Dr Bruce Aylward, Senior Advisor to the Director-General

Upcoming Q3 COVAX supply and WHO/WTO High Level Dialogue on Expanding COVID-19 Vaccines Access

Dr Soumya Swaminathan, WHO Chief Scientist

3,717M doses of COVID-19 vaccine have been administered¹ in 216 countries, areas, territories & economies²

Total doses administered per 100 population³



3,717 M vaccine doses¹ have been administered

COVAX has **shipped 136.7M doses** to **136 participants⁴**

Immunization programmes **have not yet started in 4 countries, economies & territories²**

1. Source of data: WHO dashboard, Bloomberg; 2. Total of 220 countries, areas, territories & economies: 218 economies listed by World Bank + WHO Member states Cook Islands + Niue

3. WHO COVID-19 Dashboard at <https://covid19.who.int/>; 4. Including donations of doses through COVAX

Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

4 initiatives to increase COVAX supply and mitigate risks

Portfolio diversification

3 Advance Purchase Agreements (APAs) signed in July for almost 1 billion doses in total:

- Clover (414mn)
 - Sinovac (380mn)
 - Sinopharm (170mn)
-

Dose Sharing

- **549 million doses have been committed by countries with surplus**
-

Manufacturing taskforce

- **Aiming at increasing vaccine manufacturing capacity in LMICs**
-


Ownership transfer

Dose ownership transfer models like reselling, market place and exchange could help alleviate supply-demand mismatches and risk mitigation

1.75bn COVAX funded doses are expected to be delivered in the second half of 2021, with 1.36bn in Quarter 4

COVAX Available Supply, Cumulative, M doses, 2021

■ AMC ■ Max. SFP volume² □ Confirmed dose donations³



1 Timing of available supply is based on anticipated date of release of doses from manufacturers. Volumes for expected single-dose regimen candidates doubled to ensure comparability across vaccines. Volumes have been rounded to nearest 5mn, except those less than 10mn, and so totals may not equal sum of segments.


2 Final SFP volumes may be lower than forecasted based on opt-out and dose-sharing behavior. Volumes only account for current SFP demand based on Commitment Agreements.

3 "Dose donations" are estimated based upon commitments from donors to share new doses with COVAX. The transfer of COVAX allocations between COVAX Participants from SFPs to AMC Participants are already included in the AMC Participant volumes. Total donations on this chart are larger than 515mn due to doubling of single-dose candidates.

COVAX diversified its portfolio of suppliers

Timing of supply based on expected release of doses by manufacturers; there will be a lag between dose release and country delivery based on local reg approvals, supply agreements, logistics.

Mn doses



1 J&J volumes have been doubled for comparability with the other two-dose candidates in the portfolio.

2 All volumes have been rounded to nearest 5M.

Doses being made available to participants - round 5 and 6 allocations

Vaccines supply for Round 5	Total doses, M
Pfizer (APA)	12.2
Pfizer (through a procurement facilitated by USG)	60
Total Round 5	72.2

On **Friday 9 July**, participants were informed of allocated doses

Vaccines supply for Round 6	Humanitarian buffer, M doses	Total doses, M
BIBP/Sinopharm	7.3	42.6
Sinovac	7.4	42.7
Total Round 6	14.7	85.3

Participants will be informed on **Monday 26 July** on the details of their allocation

Shipments to begin in the coming weeks

WTO-WHO High-Level Dialogue: Expanding COVID-19 Vaccine Manufacture to Promote Equitable Access

Meeting on 21 July 2021

Background

Responds to IPPR recommendation:

WHO and WTO to *"convene major vaccine producing countries and manufacturers to get agreement on voluntary licensing and technology transfer arrangements for COVID-19 vaccines, including through the Medicines Patent Pool (MPP)"*.



Objectives

Contribute to current discussions on expanding vaccines **manufacturing capacity** and amplify work of **COVAX Manufacturing Task Force**

Engage key players to advance **global equitable and sustainable access** vaccines

Maintain momentum towards more systematic and coordinated **international action**

Status

First meeting held **21 July 2021**

Speakers included senior representatives from **vaccine manufacturers, high-level political representatives** from participating countries, **international organizations** and **civil society**

Summary of 3 major COVAX supply shifts



COVAX is on track to achieve its supply forecast for Sept and through 2021 with >500m doses now confirmed



There has been a substantive increase in donations to help bridge the Q3 gap



COVAX has more than doubled its number of suppliers for Q3 which will further reduce the risk of supply gaps (i.e. to 7+ products)


Absorptive capacity for vaccines in LICs & LMICs

Dr Kate O' Brien, Director, Department of Immunization, Vaccines and Biologicals

The speed of rollout varies enormously between countries: 1.4 doses per 100 in LICs vs. 88.8 doses per 100 in HICs




Cumulative COVID-19 doses administered per 100 population




SOURCE: Our World in Data (Dec-Mar 7); WHO Dashboard (Mar 12 onwards); source for income groups: World Bank. Using the latest available values for each week.

At the aggregate level, AMC portfolio (excl. India) will remain supply-constrained till end of 2021



When taking into account other supply sources, the required lift in absorption appears even more drastic

Q4¹ Vx supply to AMC91 (excl. India), M doses




1. Assuming that 75% of the 2021 Vx supply are made available in Q4
 2. Includes dose-sharing. Assuming (i) 20% of all AMC supply goes to India, (ii) additional doses go to AMC countries, of which 20% go to India
 3. An additional AU 243M doses are currently under negotiation for delivery in Q4

Source: COVAX supply forecast, IMF supply data as of 23 June, WHO dashboard

Supply surge in Q4: AMC91 countries are estimated to receive **1.9bn doses**

In order to absorb such volumes, countries need to take action now: E.g. start planning, put operational funding in place, scale health care workforce

However, low-uptake countries could face challenges absorbing volumes as of Sep 2021



Takeaways:

- Some countries will face **difficulties absorbing all volumes supplied starting September 2021**
- Long-term goal of the monitoring will be to support countries' move to higher **absorptive capacity**

Countries need to take actions in 4 primary areas to prepare for the Vx supply surge (1/2)

1



National planning and costing

Action to be taken

Update national vaccination plans to account for the increased supply, e.g. ramping up cold chain or submitting costing needs

2



HR surge and technical teams

Strategize around the ramp up of HW and work closely with emergency and humanitarian actors

Support provided through COVAX

Simplified costing tool has been developed through the Partners Platform as well as a guide to NDVP 2.0.

Training sessions are organized and available to countries

Closely monitoring HR surge cost
Technical experts' support is available to countries via GOARN

Countries need to take actions in 4 primary areas to prepare for the Vx supply surge (2/2)

3



Cold chain equipment

Action to be taken

Ensure sufficient storage capacity at the national & subnational levels – accommodating for different Vx products

Support provided through COVAX

Gavi CCEOP provides cold chain support to countries
The CRD supply and logistics Working Group is managing CCE needs

4



Service delivery

Ensure sufficient in country service delivery capacity and have comprehensive micro-planning strategies in place

CRD has developed a microplanning guidance that has been made available to countries

Beyond that, multiple Vx products in programmes poses challenges



Actions to be taken to accommodate for different vaccine products

- Policy adjustments on mix-match as evidence evolves
- Human resources need product specific training/guidance
- Delivery strategies need to fit product specificities
- Clear coordination is needed around delivery schedules/prioritization
- Cold chain capacity for the different product requirements needs to be ensured
- Efficient track and trace processes need to be in place including for AEFI reporting and for compensation mechanisms

Implementation Monitoring Review (IMR) to assess the challenges countries face in rolling out C19 vaccines


Six main categories of bottlenecks have been identified and are currently being addresses

Vaccine hesitancy	A Confidence and Uptake Task Team has been established to monitor issues around demand, uptake, and hesitancy – social listening in place in several countries.
Slow vaccine uptake	A task team has been established to understand COVID-19 vaccine absorption rates in countries.
Vaccines expiring before usage	Guidance on prioritization of using vaccines with varying expiry dates. SAGE published updated guidance on 1st and 2nd dose intervals.
Limited operational funding available in country	Gavi Covid vx Delivery Support funding was officially launched on July 5 th UNICEF allocated \$40 million to country offices
Low reporting of safety concerns	Global webinar on this issue have been completed
Limited supply and lack of visibility on next shipments	Ongoing COVAX communication on supply to countries

Additional category being added on impact of COVID-19 on routine immunization

To mitigate the anticipated challenges, CRD has taken several steps

The NDVP 2.0, an updated guidance on how to develop a national deployment and vaccination plan for COVID-19, was published



Countries can submit their budget needs to the Partners Platform and donors can share information on available resources



COVAX is currently developing a guidance on human resource surge capacity which will be available to countries this week

